Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers.
Robert B KargboPublished in: ACS medicinal chemistry letters (2023)
This Patent Highlight discusses novel therapeutic strategies for treating cancers associated with TP53 or KRAS mutations, particularly colorectal, pancreatic, and non-small-cell lung cancers. It focuses on the use of combination therapies involving two distinct compounds and a KRAS inhibitor. Researchers are exploring the effectiveness of these combined therapies in patient treatment and investigating their potential applications in drug manufacturing. With cancer being a global health challenge, these innovative strategies could present a breakthrough in enhancing survival rates and improving the quality of life for patients.
Keyphrases
- global health
- randomized controlled trial
- systematic review
- ejection fraction
- public health
- wild type
- case report
- prognostic factors
- papillary thyroid
- cell therapy
- chronic kidney disease
- patient reported outcomes
- combination therapy
- drug delivery
- risk assessment
- cancer therapy
- human health
- patient reported
- lymph node metastasis